The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

When it comes to losing fat without extreme exercise, only a few medicines are worth considering. With the innovation in the medical world, physicians are now recommending the Ozempic weight loss ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Ozempic came out with a higher-strength, 2 mg dose that was not approved until after this trial was over. Considering GLP-1 agonists tend to perform better at higher doses, it remains to be seen ...

The development of more potent and longer-acting synthetic analog incretin mimetics, particularly semaglutide (Ozempic/Wegovy ... doses of semaglutide ( 2 mg) would provide greater benefit ...

Few drugs have captured public attention like Ozempic; many of us have even taken it. The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.